Staff editor

AI implementation for microbiome small molecule discovery & therapeutics

Antonio Gomes, Principal Scientist at Xbiome, talks about employing deep learning techniques to refine the prediction of natural product structures directly from gene sets.

Innovative partnership between Resilient Biotics and Cosmosid sets a new horizon in microbiome research

The two companies will work on identifying, analyzing, and understanding respiratory tract microbiome systems.

Why microbiome therapies are the next frontier in oncology

Elran Haber, CEO at Biomica Ltd, discussed the emerging role of microbiome-based treatments in cancer care.

Expanding Horizons in Microbiome Therapeutics: List Biotherapeutics and Sacco System Forge Strategic Alliance

This partnership emerges as a strategic move to capitalize on the expanding global microbiome market.

Probiotics for women’s health: new evidence in post-menopausal women

Harnessing the benefits of L. plantarum PBS067, L. rhamnosus LRH020, and B. lactis BL050 for post-menopausal symptom relief.

Freya Biosciences: pioneering the development of microbial immunotherapies for women’s health

Johan van Hylckama Vlieg, CSO and Co-founder of Freya Biosciences, discusses the latest advancements in microbial immunotherapies for women's health.

The PICASSO trial: painting a new future for melanoma patients

MaaT Pharma indicates completion of patient recruitment for the Phase 2a RCT Evaluating MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma.

Clinical Microbiomics acquires DNASense to expand frontier technologies

This strategic acquisition is set to reshape the landscape of microbiome research, extending its applications far beyond human health.

Innovative Frontiers: AI-Driven Approaches to Microbiological Analysis

An open discussion about the future of microbiological analysis through AI integration with Franco Pirovano (Micro srl) and Federico Pirovano (Dynius).

Engineering Live biotherapeutics to treat complex respiratory diseases

Maria Lluch Senar, Founder and Chief Scientific Officer at Pulmobiotics SL, discusses the research on engineering Live Biotherapeutics in order to expose antigens or deliver therapeutic agents to treat complex…

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top